LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by Barrington Research

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by investment analysts at Barrington Research from an “outperform” rating to a “market perform” rating in a research note issued on Friday, Marketbeat.com reports. Barrington Research also issued estimates for LeMaitre Vascular’s Q3 2025 earnings at $0.57 EPS, Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.60 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.68 EPS and FY2026 earnings at $2.62 EPS.

A number of other equities analysts have also recently weighed in on the stock. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer reissued an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus price target of $95.25.

LeMaitre Vascular Stock Performance

LMAT opened at $91.85 on Friday. The company has a fifty day moving average price of $96.89 and a two-hundred day moving average price of $94.73. The firm has a market capitalization of $2.07 billion, a PE ratio of 50.19, a P/E/G ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a 52 week low of $62.39 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. Equities analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors have recently added to or reduced their stakes in the stock. New York State Teachers Retirement System lifted its position in LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after buying an additional 100 shares in the last quarter. Flputnam Investment Management Co. lifted its position in LeMaitre Vascular by 3.6% during the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after buying an additional 102 shares in the last quarter. Norden Group LLC lifted its position in LeMaitre Vascular by 4.5% during the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock worth $218,000 after buying an additional 103 shares in the last quarter. Blue Barn Wealth LLC lifted its position in LeMaitre Vascular by 4.4% during the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock worth $229,000 after buying an additional 104 shares in the last quarter. Finally, Shaker Investments LLC OH lifted its position in LeMaitre Vascular by 0.8% during the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock worth $1,285,000 after buying an additional 112 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.